雷洛昔芬对绝经期后乳腺癌VEGF、Ki-67、CD34抗原表达的影响  

Influence of Raloxifene on VEGF, Ki-67 and CD34 Antigen Expression in Postmenopausal Women with Breast Carcinoma

作　　者：侍晓辰[1] 张卫东[1] 周仕萍[1] 

机构地区：[1]无锡市中医医院普外科,江苏214001

出　　处：《天津医药》2012年第3期206-208,共3页Tianjin Medical Journal

摘　　要：目的:探讨雷洛昔芬对绝经期后乳腺癌血管内皮生长因子(VEGF)、Ki-67、CD34抗原表达的影响及其意义。方法:20例绝经期后乳腺浸润性导管癌(TNM分期Ⅱ期,雌激素受体阳性)女性口服雷洛昔芬60mg/d,连续用药21d后行乳腺癌改良根治术,术后采用免疫组化法检测治疗前后肿瘤组织VEGF、Ki-67、CD34抗原表达情况,对所得结果进行比较分析。结果:雷洛昔芬治疗前后VEGF表达阳性率分别为85%(17/20)和30%(6/20),差异有统计学意义(χ2=12.38,P<0.01)。雷洛昔芬治疗前后Ki-67阳性细胞百分数分别为(19.36±1.66)%和(12.24±1.42)%,差异有统计学意义(t=2.86,P<0.01)。雷洛昔芬治疗前后CD-34抗原标记的肿瘤微血管数量分别为46.25±3.88和23.64±1.53,差异有统计学意义(t=2.93,P<0.01)。结论:雷洛昔芬可抑制绝经期后女性乳腺癌肿瘤细胞的增殖活性及肿瘤组织的微血管形成,这一作用可能是通过抑制肿瘤VEGF的表达实现的。Objective： To explore the influence of raloxifene on vascular endothelial growth factor （VEGF）, Ki-67 and CD34 antigen expression in postmenopausal women with breast carcinoma. Methods： Twenty postmenopausal patients with TMN stage II and estrogen receptor （＋） breast cancer were involved in this research. All of these patients took orally raloxifene 60 mg/d for 21 days. Immunohistochemistry was carried out in tumor samples to evaluate VEGF, Ki-67 and CD34 antigen expression before and after raloxifene treatment, respectively. Results： The positive expression rates of VEGF were 85% （17/20） and 30% （6/20） before and after raloxifene treatment, the difference was significant （χ2 = 12.38, P 〈 0.01）. The percentage rates of Ki-67 positive cells were （19.36±1.66）% and （12.24±1.42）% before and after raloxifene treatment respectively, which was significantly different （t = 2.86, P 〈 0.01）. The mean number of microvessels was 46.25±3.88 before raloxifene therapy and 23.64±1.53 after raloxifene therapy （t = 2.93, P 〈 0.01）. Conclusion： Raloxifene has an inhibitory effect on proliferation and angiogenesis of breast carcinoma tissue in postmenopausal women, which might be involved in depressing VEGF expression of tumor tissue.

关 键 词：乳腺肿瘤 癌 绝经期 雷洛昔芬 血管内皮生长因子类 Ki-67抗原抗原 CD34 免疫组织化学 

分 类 号：R733.710.3[医药卫生—肿瘤]